| Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. | |
| | |
MedLine Citation:
|
PMID: 19430310 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Loop diuretics could adversely influence prognosis due to activation of neurohumoral mechanism in the long term. Previous study showed torasemide, a loop diuretic with anti-aldosteronergic properties, was associated with lower mortality in patients with chronic heart failure (CHF). We evaluated the effects of torasemide, in comparison with azosemide, in patients with CHF. Patients received oral diuretic therapy with torasemide (8 mg/d, n = 15) or azosemide (60 mg/d, n = 15) for 3 months. Torasemide and azosemide were then switched, and the patients were treated for another 3 months. Torasemide treatment induced significant decreases in left ventricular (LV) systolic wall stress (from 259 +/- 95 to 232 +/- 80 kdyn/cm2) and the plasma level of aldosterone (from 133 +/- 61 to 95 +/- 50 pg/mL) and was not associated with a change in the plasma level of norepinephrine. In contrast, the plasma level of norepinephrine was significantly increased (from 370 +/- 170 to 481 +/- 247 pg/mL), whereas LV systolic wall stress was unchanged after azosemide treatment. This study indicates that torasemide treatment reduced LV systolic wall stress without activation of the sympathetic nervous system in patients with CHF. The anti-aldosteronergic properties of torasemide may contribute to its favorable effects. |
| | |
Authors:
|
Ken Harada; Hideo Izawa; Takao Nishizawa; Akihiro Hirashiki; Yosuke Murase; Masakazu Kobayashi; Satoshi Isobe; Xian Wu Cheng; Akiko Noda; Kohzo Nagata; Mitsuhiro Yokota; Toyoaki Murohara |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 53 ISSN: 1533-4023 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-22 Completed Date: 2009-10-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 468-73 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. haraken@med.nagoya-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Aldosterone / blood Aldosterone Antagonists / therapeutic use* Cross-Over Studies Delayed-Action Preparations Drug Administration Schedule Female Heart Failure / drug therapy, physiopathology Humans Male Middle Aged Norepinephrine / blood Sodium Potassium Chloride Symporter Inhibitors / therapeutic use* Sulfanilamides / therapeutic use* Sulfonamides / therapeutic use* Sympathetic Nervous System / drug effects*, physiopathology Systole Ventricular Dysfunction, Left / drug therapy*, physiopathology |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Delayed-Action Preparations; 0/Sodium Potassium Chloride Symporter Inhibitors; 0/Sulfanilamides; 0/Sulfonamides; 27589-33-9/azosemid; 51-41-2/Norepinephrine; 52-39-1/Aldosterone; 56211-40-6/torsemide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The prototype serotonin 5-HT 1B/1D agonist sumatriptan increases the severity of myocardial ischemia...
Next Document: Case based e-learning in occupational medicine--a European approach.